$7,05
▲ +$0,03
(+0,43%)
Vol. 1.7M
10
Punteggio di Qualità
ok
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$916.3M
P/E
5,6
ROE
81,8%
Margine
75,8%
D/E
38,93
Beta
1,45
52W
$6–$17
Consenso Wall Street
13 analisti · Apr 20263
Acquisto forte
9
Compra
1
Mantieni
0
Vendi
0
Vendita forte
92,3%
Rating Compra
Grafico dei Prezzi
Titoli simili
ESPR
Esperion Therapeutics Inc
$884.5M
LBRX
LB Pharmaceuticals Inc
$563.2M
ZVRA
Zevra Therapeutics Inc
P/E 14,3
$504.4M
FULC
Fulcrum Therapeutics Inc
$746.1M
ACRS
Aclaris Therapeutics Inc
$326.1M
AQST
Aquestive Therapeutics Inc
$788.1M
AVIR
Atea Pharmaceuticals Inc
$278.9M
CTNM
Contineum Therapeutics Inc
$417.5M
Utili
Tasso di battuta: 75,0%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Dic 2025 | $0,83 | $0,18 | $-0,65 |
| Set 2025 | $0,66 | $1,26 | +$0,60 |
| Giu 2025 | $0,18 | $0,28 | +$0,10 |
| Mar 2025 | $0,27 | $0,30 | +$0,03 |
Ricavi e utili trimestrali
| Trimestre | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Ricavi | $31.2M | $39.1M | $39.7M | $104.3M | $128.6M |
| Utile netto | $13.5M | $20.6M | $19.8M | $108.6M | $14.0M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 42.7% | 42.7% | 42.7% | 42.7% | 81.8% | 81.8% |
| P/E (TTM) | 17.90 | 19.06 | 17.75 | 17.05 | 4.74 | 5.64 |
| Net Margin | 49.9% | 42.1% | 42.1% | 42.1% | 75.8% | 75.8% |
| Gross Margin | 95.3% | 95.6% | 95.6% | 95.6% | 92.6% | 92.6% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 38.93 | 38.93 |
| Current Ratio | 7.82 | 7.82 | 7.82 | 7.82 | 1.94 | 1.94 |
Rapporti chiave
ROA (TTM)
51,1%
P/S (TTM)
4,28
P/B
5,8
EPS (TTM)
$2,05
CF/Share
$-0,85
Crescita ricavi 3A
+511,6%
52W High
$17,43
52W Low
$5,60
$5,60
Intervallo 52 settimane
$17,43
Salute finanziaria
Flusso di cassa libero
$92.7M
Debito netto
$4.1M
Liquidità
$144.8M
Debito totale
$148.9M
Aggiornato al Dic 31, 2025
Як CRMD виглядає на тлі конкурентів у Pharmaceuticals?
Група порівняння: Micro-cap Pharmaceuticals (All) · 171 компаній
Оцінка CRMD vs аналоги Pharmaceuticals
P/E
5,6
▼
75%
sotto
peer
(22,4)
vs Peer
vs Settore
Sottovalutato
P/S
4,3
▼
14%
sotto
peer
(5,0)
vs Peer
vs Settore
Valore equo
P/B
5,8
▲
174%
sopra
peer
(2,1)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(2,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість CRMD vs аналоги Pharmaceuticals
ROE
81,8%
▲
251%
sopra
peer
(-54,3%)
vs Peer
vs Settore
Top livello
Net margin
75,8%
▲
260%
sopra
peer
(-47,4%)
vs Peer
vs Settore
Sotto media
Валова маржа
92,6%
▲
36%
sopra
peer
(68,3%)
vs Peer
vs Settore
Sotto media
ROA
51,1%
▲
236%
sopra
peer
(-37,4%)
vs Peer
vs Settore
Top livello
Фінансове здоровʼя CRMD vs аналоги Pharmaceuticals
D/E ratio
38,9
▲
2428%
sopra
peer
(1,5)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
1,9
▼
42%
sotto
peer
(3,4)
vs Peer
vs Settore
Liquidità bassa
Beta
1,5
▲
54%
sopra
peer
(0,9)
vs Peer
vs Settore
Più volatile
Радар фундаменталів CRMD
CRMD
Mediana peer
Industria
CRMD прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
CRMD vs аналоги: ключові метрики
Ultime notizie
Nessuna notizia correlata ancora